Today's Analyst Rating Data for MGNX: Major Upgrade by B. Riley
B. Riley Securities has upgraded Macrogenics (MGNX) from Neutral to Buy, significantly increasing its price target from $3.00 to $9.00, suggesting a 200% growth potential. This upgrade reflects a shifting positive sentiment for the clinical-stage biopharmaceutical company, which focuses on developing antibody-based therapeutics for cancer using various modalities. Despite the upgrade, the average analyst price target for MGNX is $4.00, with a consensus "Hold" status from seven brokerage firms.
APR 9·Investing.com Australia▲
MacroGenics resumes enrollment in lorigerlimab cancer study By Investing.com
MacroGenics Inc. announced that the U.S. FDA has lifted a partial clinical hold on its Phase 2 LINNET study for lorigerlimab in gynecologic cancers, allowing for the enrollment of new participants under a revised protocol. This decision has been met with investor optimism, reflected in the stock's recent surge. The company anticipates providing a mid-year clinical update on the program.
APR 9·TradingView▲
FDA Lifts Partial Clinical Hold on MacroGenics' LINNET Study; Enrollment to Resume
The FDA has removed the partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab, allowing patient enrollment to continue. This decision follows a revised protocol incorporating additional risk-mitigation measures for potential hematologic and cardiac toxicities. MacroGenics expects to provide a clinical update on the program in mid-2026.
